Headquartered in Louvain-La-Neuve, Belgium, IBA (Ion Beam Applications S.A.), a global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, has signed a contract to establish the first proton therapy center in India. The agreement with Apollo Hospitals, Asia’s largest integrated healthcare group and India’s no.1 private hospital presents a very exciting opportunity for IBA to address the region’s growing need for high quality treatment.
With approximately three million people suffering from cancer and one million new cases detected every year in India, IBA recognized the need for specialty cancer treatment hospitals. As a result, IBA will be supplying an estimated €50 million worth of equipment and services to the Apollo Proton Therapy Center of which has been fully financed and also includes a long-term operation and maintenance contract. In fact the new center will be equipped with IBA’s Proteus®PLUS multi-room configuration, which includes three treatment rooms outfitted with Pencil Beam Scanning capabilities. IBA will also provide all dosimetry equipment to ensure the safest and fastest implementation of the center allowing patients to benefit from proton therapy as of 2016.
As access to proton therapy increases in Europe and across the world, this collaboration with India is an example of how IBA has continued to demonstrate compassionate innovations by providing more patient-friendly facilities and specific therapies to areas in great need of such treatments. Since most patients are diagnosed with advanced stage cancer, the demand for this level of state-of-the-art cancer treatment is very high. Today, proton therapy is used to treat many cancers particularly in situations where treatment options are limited and conventional radiation therapy presents a greater risk to the patient: eye and brain cancers; tumors close to the brain stem and spinal cord; prostate, liver, lung and breast cancers; and pediatric cancers.
Olivier Legrain, CEO of IBA, has expressed his excitement in making proton therapy available for the first time in India and has recognized, with the Indian healthcare market growing rapidly, there is a significant need for innovative approaches to cancer therapy. Through this collaboration with Apollo, Legrain has further acknowledged that this will strengthen its world leading position in proton therapy and will position IBA at the forefront of delivering innovative cancer therapy treatment to the entire Asia region.
From the Apollo Hospitals standpoint, Dr. Reddy, Chairman of Apollo Hospitals Group, has correspondingly expressed the benefits of the new proton therapy facility citing: it will enhance the ability to provide superior cancer care by providing patients access to the most advanced radiation therapy technology; become an International Proton Therapy Center of Reference in Asia; and promote the benefits of proton therapy technology across the sub-continent.
To date, IBA proton systems are integrated in more than half of the clinically based proton therapy facilities worldwide comprising 13 operational proton therapy centers and 12 more centers in development. In addition to the systems already installed across Europe and the US, this expansion into India will allow IBA to deliver radiation therapy and state-of-the-art cancer treatments for the millions of patients currently suffering from cancer in India and other Asian regions.
In their efforts to improve the treatment for cancer patients, it seems this IBA and Apollo Hospitals collaboration could prove to be a “win-win” situation for all!
Chief Financial Officer
+32 10 201 287
Vice-President Corporate Communication
+32 10 201 287
For media and investor enquiries:
Mary-Jane Elliott, Amber Bielecka,Claire Dickinson
+44 (0) 207 920 2333